External validation of the 8(th) American Joint Committee on Cancer staging system for gall bladder carcinoma

对美国癌症联合委员会第8版胆囊癌分期系统进行外部验证

阅读:1

Abstract

BACKGROUND: To validate the changes within the American Joint Committee on Cancer (AJCC) 8(th) staging system for gall bladder carcinoma compared to AJCC 7(th) staging system. METHODS: Surveillance, Epidemiology and End Results (SEER) database [2004-2014] was queried. Kaplan-Meier survival analyses and Log-rank testing were assessed according to both AJCC 7(th) and 8(th) staging systems. Likewise, Cox cancer-specific hazard ratio was evaluated according to both staging systems. RESULTS: Overall survival was assessed according to the two staging systems; and P values for overall trend (log/rank test) were significant (P<0.001) for both scenarios. Cox regression cancer-specific hazard adjusted for age, gender, histology, gender and surgery was evaluated according to the two staging systems. According to AJCC 7(th) staging system, the following pair wise hazard ratio comparisons were significant (II vs. IIIA; IIIB vs. IVA; IVA vs. IVB). According to AJCC 8(th) staging system, the following pair wise hazard ratio comparisons were significant (II vs. IIIA; IVA vs. IVB). C-statistic was assessed using death from gall bladder carcinoma as the dependent variable; and the findings for the two staging systems were as follows: AJCC 7(th) staging system: 0.684 (SE: 0.008; 95% CI: 0.667-0.701); AJCC 8(th) staging system: 0.682 (SE: 0.009; 95% CI: 0.665-0.698). CONCLUSIONS: There is a comparable discriminatory performance for AJCC 8(th) staging system compared to AJCC 7(th) staging system. Change form location-based to number-based N category assessment does not improve the overall prognostic performance of the staging system.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。